Pharmacy Grand Rounds
GABbing About Pain: Perioperative Use of Gabapentinoids for Acute Pain Management

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

2016 American Pain Society guidelines on the management of postoperative pain recommend that clinicians consider use of gabapentinoids as a part of perioperative pain management. Current literature calls into question the appropriateness of the gabapentinoids due to a lack of efficacy, increase in adverse effects, potential for abuse, and toxicity risk. This presentation will review current literature and provide insight into appropriate use of gabapentinoids for acute pain in the perioperative patient population.

At the conclusion of this knowledge-based CE session, participants should be able to:

• Describe the pharmacology of the gabapentinoids
• Review literature pertaining to perioperative gabapentinoid use for acute pain management
• Identify toxicity, misuse, and abuse considerations relating to gabapentinoid use

Session Announcement

Session Slides

FACULTY INFORMATION

Joseph C. Osborne II, PharmD
PGY1 Health-System Pharmacy Administration Resident
Mayo Clinic Hospital - Rochester, MN

Joseph received a Doctor of Pharmacy degree from Ferris State University in Big Rapids, MI. He is a current PGY1 Health-System Pharmacy Administration Resident at Mayo Clinic Hospital – Rochester with practice interests in regulatory affairs, quality improvement and pharmacy practice advancement.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Joseph C. Osborne II, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Gabapentin
    • Pregabalin

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS